Long cycles, committee buyers,
and forecasts that lie.

Selling devices into hospitals and software into practices means 9 to 18 month cycles, Value Analysis Committees, and clinical plus economic buyers who both must say yes. Generic pipeline math breaks here. The structure has to fit the sale.

Healthcare and MedTech is one of the hardest revenue environments in B2B, and most of the forecasting tools companies use were built for something else entirely. A 30 day SaaS playbook applied to an 18 month hospital device sale does not just underperform. It produces a forecast that is confidently, expensively wrong.

The committee is the real buyer

In hospital sales, the person who loves your product is rarely the person who can buy it. A clinical champion gets you in the door, but the Value Analysis Committee decides, and that committee takes 3 to 6 months and meets only monthly or quarterly. Add GPO and IDN contracting and you have a second approval layer on top of the first. A pipeline that scores these deals on the champion enthusiasm alone is reading the wrong signal.

The stakes of getting it wrong are unusually high. A VAC rejection can lock a vendor out for 12 to 24 months before reconsideration. In most industries a lost deal is a lost deal; in MedTech a lost deal can close the account for two years. That makes qualification rigor and stage discipline not just useful but financially decisive.

Why the cycle length hides the leak

When deals take a year or more, problems stay invisible for a long time. A broken qualification standard or a missing economic buyer will not show up in this quarter’s number; it shows up four quarters out, when the deals that should have closed simply do not. By then the cause is buried under a year of activity. This is exactly why MedTech companies can look busy and pipelined for years while the forecast quietly drifts from reality.

The fix is structural. The Sales Lab Engine™ scores all five pillars, then applies the healthcare overlay: cycle expectations segmented by what is actually sold, committee dynamics built into the stages, and the dual champion plus economic buyer requirement made explicit. The benchmarks are honest about their limits too. There is no credible public benchmark for dental equipment cycles, and device specific win rates are held privately by firms like ZS and Alexander Group, so the diagnostic anchors on what is verifiable and flags what is not.

Common questions

Score your revenue system
against the MedTech reality.

The diagnostic applies healthcare and MedTech benchmarks across all five pillars and shows where your committee driven, long cycle revenue is leaking. Complimentary, reviewed personally by founder Reza Nazarinia.